PMID- 32950267
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20210827
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 81
IP  - 12
DP  - 2020 Dec
TI  - TRBV and TRBJ usage, when paired with specific HLA alleles, associates with 
      distinct head and neck cancer survival rates.
PG  - 692-696
LID - S0198-8859(20)30391-8 [pii]
LID - 10.1016/j.humimm.2020.08.007 [doi]
AB  - Common or dominant, T-cell receptor (TCR), V and J usage, in combination with 
      particular human leukocyte antigen (HLA) alleles, has been associated with 
      differing outcomes in viral infections, autoimmunity, and more recently, in 
      cancer. Cervical cancer in particular represents the most dramatic series of 
      distinctions of outcomes associated with differing combinations of dominant V or 
      J usage and HLA alleles, possibly because of the strong association of cervical 
      cancer with human papilloma virus (HPV), in turn leading to a likely molecular 
      consistency in the mechanism of HPV antigen presentation. Thus, we considered 
      assessing TRB V and J usage, HLA allele combinations, for their associations with 
      survival rates and related data, in the cancer genome atlas head and neck cancer 
      dataset. We obtained the TRB VDJ recombination reads from both the blood and 
      tumor exome files and determined the V and J identities. We then established case 
      ID (patient) subsets of V or J usage, HLA alleles, and determined, for example, 
      that the TRBJ2-7, HLA-B*40:01 combination was associated with a better disease 
      free survival rate than were either the TRBJ1-3, HLA-DPB1*03:01 or the TRBJ2-1, 
      HLA-DPB1*02:01 combinations. Furthermore, these analyses led to the conclusion 
      that TRBJ1-5 usage, and the HLA-C*08:02 and HLA-DRB1*03:01 alleles, had 
      independent associations with distinct overall survival rates. In sum, the 
      results suggest that dominant V or J usage, HLA allele combinations, and in 
      certain cases, dominant V or J usage independently of HLA, could be useful in 
      prognosis and in guiding immunotherapies.
CI  - Copyright (c) 2020 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Arndt, Mary F
AU  - Arndt MF
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Koohestani, Darush M
AU  - Koohestani DM
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Chobrutskiy, Boris I
AU  - Chobrutskiy BI
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Mihyu, Moody M
AU  - Mihyu MM
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Diaz, Michael
AU  - Diaz M
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Gozlan, Etienne C
AU  - Gozlan EC
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Yeagley, Michelle
AU  - Yeagley M
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Zaman, Saif
AU  - Zaman S
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Roca, Andrea M
AU  - Roca AM
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States.
FAU - Blanck, George
AU  - Blanck G
AD  - Department of Molecular Medicine, Morsani College of Medicine, University of 
      South Florida, United States; Department of Immunology, H. Lee Moffitt Cancer 
      Center and Research Institute, Tampa, FL 33612, United States. Electronic 
      address: gblanck@usf.edu.
LA  - eng
PT  - Journal Article
DEP - 20200916
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
SB  - IM
MH  - *Alleles
MH  - Biomarkers, Tumor/blood/genetics
MH  - Disease-Free Survival
MH  - Exome
MH  - *Genes, T-Cell Receptor beta
MH  - HLA Antigens/*genetics
MH  - Head and Neck Neoplasms/blood/*genetics/*mortality/pathology
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Prognosis
MH  - Receptors, Antigen, T-Cell, alpha-beta/*genetics
MH  - Survival Rate
MH  - *V(D)J Recombination
OTO - NOTNLM
OT  - Dominant TRBV and TRBJ usage
OT  - HLA
OT  - HPV
OT  - Head and neck cancer
OT  - Immune biomarkers
OT  - Immunotherapy
OT  - Survival rates
OT  - T-lymphocyte infiltrates
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/09/21 06:00
MHDA- 2021/08/28 06:00
CRDT- 2020/09/20 20:25
PHST- 2020/04/23 00:00 [received]
PHST- 2020/08/27 00:00 [revised]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/09/21 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2020/09/20 20:25 [entrez]
AID - S0198-8859(20)30391-8 [pii]
AID - 10.1016/j.humimm.2020.08.007 [doi]
PST - ppublish
SO  - Hum Immunol. 2020 Dec;81(12):692-696. doi: 10.1016/j.humimm.2020.08.007. Epub 
      2020 Sep 16.